PAE vs. UroLift vs. Rezum: Which Fits Your Prostate?
All three avoid the downsides of TURP. They are not interchangeable — gland size, median lobe anatomy and durability separate them.
Find out in under a minute – no phone call needed.
On this page
If a urologist has offered you UroLift or Rezum, you have been offered a good procedure. Whether it is the right one depends on facts about your prostate that often do not come up in a fifteen-minute appointment: how large it is, whether you have a median lobe, and how much you care about ejaculation. All three of these treatments avoid the downsides of TURP. They are not interchangeable.
Three Different Mechanisms
Understanding what each one physically does explains most of the differences between them.
- UroLift (prostatic urethral lift) places permanent implants that pull the prostate lobes apart, holding the urethra open. Nothing is removed or destroyed — the obstruction is retracted rather than reduced.
- Rezum (water vapor thermal therapy) injects steam into the prostate tissue. The heat destroys cells, and the body reabsorbs them over the following months, so the gland genuinely shrinks.
- PAE (prostate artery embolization) blocks the arteries feeding the prostate from inside the blood vessels. The gland shrinks from reduced blood supply. Nothing enters the urethra at all.
That third point matters more than it sounds. UroLift and Rezum are both transurethral: an instrument passes through the penis into the prostatic urethra. PAE is endovascular, reached through a pinhole in the wrist or groin. It is the only one of the three that never touches the urinary tract.
Side by Side
| PAE | UroLift | Rezum | |
|---|---|---|---|
| Route | Through an artery, wrist or groin | Through the urethra | Through the urethra |
| Gland size limit | None in practice; data above 200 mL | Generally under 80 mL | Generally 30–80 mL |
| Median lobe | Not an obstacle | Obstructing median lobe is a problem; excluded from the pivotal trial | Can be treated; 31% of the pivotal trial had one |
| Catheter afterwards | Usually none | Often none or brief | Typically several days |
| Speed of relief | Gradual, over weeks to months | Fast — mechanical effect is immediate | Gradual, roughly 3 months |
| 5-year surgical retreatment | Roughly 16–21% | 13.6% in the pivotal trial | 4.4% in the pivotal trial |
| Ejaculation | Preserved | Preserved | Largely preserved |
| Anesthesia | Local plus sedation | Local or sedation | Sedation or general |
All three preserve ejaculation, which is the shared advantage over TURP and HoLEP. Where they diverge is which prostates they can treat and how long the result holds.
Who Each One Rules Out
This is the part most worth checking against your own imaging, because it is where men get quietly excluded.
UroLift
Designed for glands generally under 80 mL, and the pivotal trial excluded men with an enlarged median lobe. If your prostate has a median lobe pushing up into the bladder, the implants have nothing useful to retract. Some operators now treat median lobes with modified technique, but it remains the classic limitation.
Rezum
Studied mainly in the 30–80 mL range, though it is used above that. In a four-year comparison, men with glands of 80–120 g did well but needed retreatment significantly more often — 15.2% — than men with smaller prostates. It handles median lobes well, which is its main advantage over UroLift. The trade is a catheter for several days afterwards and a period of irritative symptoms while the treated tissue is reabsorbed.
PAE
Has no practical upper size limit and works regardless of median lobe. Its exclusions are different in kind: arteries too diseased or too small to navigate safely, significant kidney impairment or severe contrast allergy, active urinary infection, a bladder that has stopped contracting properly, and suspected prostate cancer. A very small prostate is also a poor target, since there is little to shrink.
Two questions to bring to your urologist
What is my prostate volume in millilitres, and do I have a median lobe? Those two facts determine which of these three you are genuinely eligible for. If you were offered UroLift without either being measured, it is fair to ask.
Durability and Retreatment
No minimally invasive treatment matches TURP or HoLEP for durability. All three trade some longevity for a gentler procedure, and they trade different amounts.
In the pivotal trials, Rezum had a 4.4% surgical retreatment rate at five years against 13.6% for UroLift, though those trials enrolled different populations — notably, UroLift excluded median lobes and Rezum did not. A direct comparison found five-year retreatment of 6.8% for Rezum versus 10.8% for UroLift, and a separate analysis found five-year cumulative complication rates of 15.4% and 33.6% respectively.
PAE sits at roughly 16–21% needing a further prostatic procedure by five years in long-term series. That is the honest number and it is higher than either alternative. What softens it is that a repeat PAE is straightforward, and in the largest long-term cohort 88% of men had still avoided prostatectomy at five years.
Set against that: PAE is the only one of the three with meaningful data in large and very large glands, which is exactly the group where UroLift and Rezum either underperform or do not apply.
Sexual Function
All three are chosen largely because they preserve ejaculation, where TURP causes retrograde ejaculation in roughly half to three-quarters of men. None of the three causes appreciable erectile dysfunction.
If this is your priority, the decision is not really between these three on sexual grounds — it is between this group and the resective operations. Our page on retrograde ejaculation after prostate surgery covers the rates procedure by procedure.
How to Think About the Choice
- Prostate under 80 mL, no median lobe, want the fastest relief — UroLift is a strong fit, accepting a higher retreatment rate over time.
- Prostate 30–80 mL, median lobe present, catheter for a few days acceptable — Rezum has the best durability data of the three.
- Prostate over 80 mL, or a large median lobe, or you cannot stop blood thinners, or you are a poor candidate for anesthesia — PAE is often the only one of the three that applies.
- Durability above all, and retrograde ejaculation is acceptable — TURP or HoLEP remain the most durable, and an honest specialist will say so.
Where Prostate Artery Embolization Fits
PAE treats an enlarged prostate from the inside of the blood vessels rather than through the urethra. A catheter is threaded from a pinhole in the wrist or groin to the small arteries feeding the prostate, and microscopic particles are released to reduce its blood supply. The gland shrinks over the following months and the pressure on the urethra eases. There is no incision, no general anesthetic, no instrument passed through the penis, and no overnight stay.
Because it works through the arteries instead of the prostatic urethra, PAE avoids the bladder neck entirely. That anatomical difference is why it behaves so differently from the transurethral procedures on the one measure men care about most and are least often asked about.
That last figure belongs here rather than buried. PAE trades durability for safety and functional preservation. Around one man in five needs something further within five years, against a much lower rate after resective surgery. In the largest long-term series, 88% of men had still avoided prostatectomy at five years, and a repeat PAE kept most of those who needed more treatment out of surgery altogether. Whether that trade is worth it depends on what you are optimising for, and it is a legitimate reason some men choose TURP or HoLEP instead.
PAE entered the American Urological Association guideline in the 2023 amendment, and the European Association of Urology guideline the same year. The previous AUA guideline had recommended against it outside clinical trials, so this is a genuine change in standing rather than marketing language — and it is the reason insurance coverage has improved. Our insurance page covers how we handle authorisation, and the office can check your benefits directly.
California Prostate Center
Atabak Allaei, MD
- Double board-certified in Vascular & Interventional Radiology and Diagnostic Radiology
- Attending staff at Cedars-Sinai Medical Center and UCI Health
- More than 10,000 image-guided procedures performed
- Focused practice in prostate artery embolization, including large glands and men who are poor candidates for surgery
Common Questions
Which is better, UroLift or Rezum?
It depends on your anatomy. Rezum has better durability data — 4.4% versus 13.6% surgical retreatment at five years in the pivotal trials — and can treat a median lobe, which UroLift traditionally cannot. UroLift gives faster relief and usually avoids a catheter. Neither is designed for prostates much above 80 mL.
Can I have UroLift with a median lobe?
The pivotal trial excluded men with an obstructing median lobe, and it remains the classic limitation, because the implants retract lobes rather than remove tissue. Some operators treat median lobes with modified technique. If you have one, Rezum and PAE both handle it more straightforwardly.
Is PAE better than UroLift or Rezum?
Not universally. PAE has a higher five-year retreatment rate than either. Its advantages are that it has no gland size ceiling, is unaffected by median lobe anatomy, requires nothing to pass through the urethra, and can be done in men who cannot stop anticoagulation or tolerate anesthesia. For a 50 mL prostate with no median lobe, all three are reasonable.
Do any of these cause erectile dysfunction?
None causes appreciable erectile dysfunction in the published data, and all three largely preserve ejaculation. That is their shared advantage over TURP and HoLEP, where retrograde ejaculation is common.
What if a previous UroLift or Rezum did not work?
Prior minimally invasive treatment does not rule out PAE, since it works through a completely different route and does not depend on the prostatic urethra being untouched. Men who have had implants placed or steam delivered and still have symptoms are a group worth evaluating rather than sending straight to TURP.
References
- Sandhu JS, Bixler BR, Dahm P, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024;211(1):11–19.
- McVary KT, et al. Final five-year results from the Rezum water vapor therapy pivotal trial: 4.4% surgical retreatment; UroLift pivotal trial 13.6% surgical retreatment at five years, which excluded median lobe enlargement.
- Comparison of Durability Between Rezum Water Vapor Therapy and UroLift: A Multicenter Propensity Score-Matched Analysis. Five-year retreatment 6.8% versus 10.8%.
- Comparing complications of Rezum and UroLift using the Accordion Severity Grading System. Five-year cumulative complication rates 15.4% versus 33.6%.
- A comparative analysis of Rezum outcomes based on prostate size: four-year retrospective analysis. Retreatment 15.2% in the 80–120 g group.
- Bilhim T, et al. Long-Term PAE Results. Prostatic reintervention 3% at 1 year, 16% at 2 years, 21% at 5 years; freedom from prostatectomy 88% at 5 years.
Find out whether PAE fits your prostate
Dr. Allaei reviews your imaging, PSA and symptom scores himself and tells you plainly whether embolization suits your anatomy, what to expect, and when another treatment is the better answer.
